It was demonstrated the high levels of CB2 expression in patients with advanced non-small-cell lung cancer and, conversely, the low expression of CB2 suppresses the Akt/mTOR pathway [23]. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.